Influence of milrinone and norepinephrine on blood flow in canine internal mammary artery grafts

Annals of Thoracic Surgery

Volumn 61, Issue 5, 1996, Pages 1367-1371

  Gitter, Richard ^a   Anderson Jr , Jerry M ^a   Jett, G Kimble ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MILRINONE; NORADRENALIN; PHENTOLAMINE;

ANIMAL EXPERIMENT; ARTICLE; CORONARY ARTERY BYPASS GRAFT; DOG; INTERNAL MAMMARY ARTERY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0029965854     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/0003-4975(96)00057-4     Document Type: Article

References (28)

1. Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal mammary artery graft on 10 year survival and other cardiac events. N Engl J Med 1986;314:1-6.
2. Hamby RI, Aintablian A, Wisoff BG, Hortstein ML. Comparative study of postoperative flow in the saphenous vein and internal mammary artery bypass grafts. Am Heart J 1977;93: 306-15.
3. Lytle BW, Loop FD, Cosgrove DM, Ratliff NB, Easley K, Taylor PC. Long-term (5-12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg 1985;89:248-58.
4. Barner HB, Standeven JW, Reese J. Twelve-year experience with internal mammary artery for coronary artery bypass. J Thorac Cardiovasc Surg 1985;90:668-75.
5. Dincer B, Barner HB. The "occluded" internal mammary artery graft: restoration of patency after apparent occlusion associated with progression of coronary disease. J Thorac Cardiovasc Surg 1983;85:318-20.
6. Singh RN, Sosa JA. Internal mammary artery: a "live" conduit for coronary bypass. J Thorac Cardiovasc Surg 1984;87:936-8.
7. Mills NL, Everson CT. Right gastroepiploic artery: a third arterial conduit for coronary artery bypass. Ann Thorac Surg 1989;47:706-11.
8. Buche M, Schoevaerdts JC, Louagie Y, et al. Use of inferior epigastric artery for coronary bypass. J Thorac Cardiovasc Surg 1992;103:665-70.
9. DiNardo JA, Bert A, Schwartz MJ, Johnson RG, Thurer RL, Weintraub RM. Effects of vasoactive drugs on flows through left internal mammary artery and saphenous vein grafts in man. J Thorac Cardiovasc Surg 1991;102:730-5.
10. Vineberg AM. Development of an anastomosis between the coronary vessels and a transplanted internal mammary artery. Can Med Assoc J 1946;55:117-9.
11. Effler DB, Sones FM Jr, Groves LK, Suarez E. Myocardial revascularization by Vineberg's internal mammary artery implant: evaluation of postoperative results. J Thorac Cardiovasc Surg 1965;50:527-33.
12. Downing SW, Edmunds LH. Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg 1992;54:1236-43.
13. Slogoff S, Keats AS. Randomized trial of anesthetic agents on outcome of coronary artery bypass operations. Anesthesiology 1989;70:179-88.
14. Jett GK, Arcidi JM, Dorsey LMA, Hatcher CR, Guyton RA. Vasoactive drug effects on blood flow in internal mammary artery and saphenous vein grafts. J Thorac Cardiovasc Surg 1987;94:2-11.
15. Jones EL, Lattouf OM, Weintraub WS. Catastrophic consequences of internal mammary artery hypoperfusion. J Thorac Cardiovasc Surg 1989;98:902-7.
16. McCormick JR, Kaneko M, Baue AE, Geha AS. Blood flow and vasoactive drug effects in internal mammary and venous bypass grafts. Circulation 1975;51, 52(Suppl 1):73-80.
17. Geha AS, Krone RJ, McCormick JR, Baue AE. Selection of coronary bypass anatomic, physiological, and angiographic considerations of vein and mammary artery grafts. J Thorac Cardiovasc Surg 1975;70:414-31.
18. Schmidt DH, Blau F, Hellman C, Grzelak L, Johnson D. Isoproterenol-induced flow responses in mammary and vein bypass grafts. J Thorac Cardiovasc Surg 1980;80:319-26.
19. Weinstein JS, Grossman W, Weintraub RM, Thurer RL, Johnson RG, Morgan KG. Differences in alpha-adrenergic responsiveness between human internal mammary arteries and saphenous veins. Circulation 1989;79:1264-70.
20. He GW, Buxten B, Rosenfeldt FL, Wilson AC, Angus JA. Weak adrenoceptor-mediated relaxation in the human internal mammary artery. J Thorac Cardiovasc Surg 1989;97: 259-66.
21. Alousi AA, Canter JM, Montenaro MJ, Fort DJ, Ferrari RA. Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals. J Cardiovasc Pharmacol 1983;5:792-803.
22. Alousi AA, Stankus GP, Stuart JC, Walton LH. Characterization of the cardiotonic effects of milrinone, a new and potent cardiac bipyridine, on isolated tissues from several animal species. J Cardiovasc Pharmacol 1983;5:804-11.
23. Anderson JL. Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States. Am Heart J 1991;121: 1956-64.
24. Feneck RO. Intravenous milrinone following cardiac surgery: II. Influence of baseline hemodynamics and patient factors on therapeutic response. J Cardiothorac Vasc Anesth 1992;6:563-7.
25. Benotti JR, Grossman W, Braunwald E, Carabello BA. Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease. Circulation 1980; 62:28-34.
26. Dupuis JY, Bondy R, Cattran C, Nathan HJ, Wynards JE. Amrinone and dobutamine as primary treatment of low cardiac output syndrome following coronary artery surgery: a comparison of their effects on hemodynamics and outcome. J Cardiothorac Vasc Anesth 1992;6:542-53.
27. Jett GK, Guyton RA, Hatcher CR, Abel PW. Inhibition of human internal mammary artery contractions. J Thorac Cardiovasc Surg 1992;104:977-82.
28. He GW, Rosenfeldt PC, Buxton BF, Angus JA. Reactivity of isolated human internal mammary artery to constrictor and dilator agents. Circulation 1989;80(Suppl 1):140-50.